keyword
MENU ▼
Read by QxMD icon Read
search

Mitraclip

keyword
https://www.readbyqxmd.com/read/29762931/mitraclip-technique-five-years-after-alfieri-stitch-mitral-valve-repair
#1
Ivaylo R Tonchev, Anna Turyan, Ronen Beeri, Mony Shuvy
The case is described of a successful MitraClip procedure performed on an 88-year-old patient with severe mitral regurgitation (MR), five years after she had undergone mitral valve repair using the Alfieri surgical procedure. It is suggested that the MitraClip procedure is an option in patients with severe MR persisting after the Alfieri procedure. Video 1: Transesophageal echocardiography before the MitraClip procedure. Severe mitral regurgitation with preserved left ventricular systolic function. The main regurgitant jet originates from the medial commissure...
September 2017: Journal of Heart Valve Disease
https://www.readbyqxmd.com/read/29762929/trileaflet-mitral-valve-treated-with-the-mitraclip%C3%A2-system
#2
Miguel Rodríguez-Santamarta, Rodrigo Estévez-Loureiro, Tomás Benito-González, Javier Gualis, Carmen Garrote, Armando Pérez de Prado, Felipe Fernández-Vázquez
A 79-year-old woman with a history of ischemic dilated cardiomyopathy, severely depressed left ventricular ejection fraction and significant mitral regurgitation (MR) was admitted to the authors´ institution for percutaneous mitral valve repair. Transesophageal echocardiography (TEE) revealed the presence of a posterior mitral cleft at the P2 level, causing a trileaflet mitral valve that contributed significantly to the regurgitant jet. The procedure was performed under general anesthesia and guided by real-time three-dimensional TEE...
September 2017: Journal of Heart Valve Disease
https://www.readbyqxmd.com/read/29759295/effect-of-acute-kidney-injury-after-percutaneous-mitral-valve-repair-on-outcome
#3
Maximilian Spieker, Katharina Hellhammer, Stratis Katsianos, Julian Wiora, Tobias Zeus, Patrick Horn, Malte Kelm, Ralf Westenfeld
Limited data exist on the occurrence of acute kidney injury (AKI) associated with percutaneous mitral valve repair (PMVR). The objectives of the present study were (1) to assess the prevalence of AKI after MitraClip (Abbott Vascular, Santa Clara, California) implantation, (2) to analyze the predictive factors of AKI, and (3) to evaluate the prognostic value of AKI after PMVR with a view to optimizing the management of high-risk patients. A total of 206 patients (serum creatinine [SCr] 1.3 ± 0.6 mg/dl, estimated glomerular filtration rate 55 ± 24 ml/min) who underwent PMVR were included...
April 17, 2018: American Journal of Cardiology
https://www.readbyqxmd.com/read/29745455/infective-endocarditis-following-transcatheter-edge-to-edge-mitral-valve-repair-a-systematic-review
#4
Lluis Asmarats, Tania Rodriguez-Gabella, Chekrallah Chamandi, Mathieu Bernier, Jonathan Beaudoin, Kim O'Connor, Eric Dumont, François Dagenais, Jean-Michel Paradis, Josep Rodés-Cabau
OBJECTIVES: To assess the clinical characteristics, management, and outcomes of patients diagnosed with infective endocarditis (IE) after edge-to-edge mitral valve repair with the MitraClip device. BACKGROUND: Transcatheter edge-to-edge mitral valve repair has emerged as an alternative to surgery in high-risk patients. However, few data exist on IE following transcatheter mitral procedures. METHODS: Four electronic databases (PubMed, Google Scholar, Embase, and Cochrane Library) were searched for original published studies on IE after edge-to-edge transcatheter mitral valve repair from 2003 to 2017...
May 10, 2018: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/29743996/emerging-transcatheter-options-for-tricuspid-regurgitation
#5
REVIEW
Ankur Kalra, Angad S Uberoi, Azeem Latib, Sahil Khera, Stephen H Little, Deepak L Bhatt, Michael J Reardon, Neal S Kleiman, Colin M Barker
Tricuspid regurgitation (TR) presents as either primary valve pathology or secondary to pulmonary or left-sided heart disease. Severe TR portends a worse prognosis independent of age, right ventricular size and function, severe left ventricular dysfunction, and increased pulmonary arterial pressures. Surgical treatment for TR has mostly been limited to patients undergoing mitral valve repair since those at high surgical risk are not candidates for traditional TR surgery. For these patients, minimally invasive techniques could be of great benefit, yet these techniques have been slow to develop because of the various anatomic and physiological aspects of the tricuspid valve apparatus...
July 2017: Methodist DeBakey Cardiovascular Journal
https://www.readbyqxmd.com/read/29743995/percutaneous-repair-of-mitral-regurgitation
#6
REVIEW
Colin M Barker
Mitral regurgitation (MR) affects more than 2 million people in the United States annually and is the second leading cause of heart valve disease after aortic stenosis. Surgical intervention is the currently accepted treatment of choice in patients with either symptomatic degenerative MR or asymptomatic MR with pulmonary hypertension, atrial fibrillation, or left ventricular dysfunction. Based on robust evidence from clinical trials, the MitraClip Transcatheter Mitral Valve Repair system (Abbott Vascular) was approved in the United States for commercial use in 2013...
July 2017: Methodist DeBakey Cardiovascular Journal
https://www.readbyqxmd.com/read/29742737/inadvertent-defibrillator-lead-placement-into-the-left-ventricle-after-mitraclip-implantation-a-case-report
#7
Giuseppe Santarpia, Francesco Passafaro, Eugenia Pasceri, Annalisa Mongiardo, Antonio Curcio, Ciro Indolfi
RATIONALE: Inadvertent pacemaker/defibrillator lead placement into the left ventricle is an unusual cardiac device-related complication and its diagnosis is not always easy and often misunderstood. Thromboembolic events are frequently associated with this procedural complication. Percutaneous lead extraction should be performed when diagnosis is made early after device implantation while long-life oral anticoagulation is a wise option when the diagnosis is delayed and the lead is not removed...
May 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29737031/delivering-value-through-volume
#8
EDITORIAL
Matthew R Watson, William A Gray
Procedural and 30-day outcomes with MitraClip are associated with center volumes. FDA approval of MitraClip led to greater volumes and trends toward improved outcomes. Possible extension of indications for MitraClip may further increase volumes.
May 1, 2018: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/29725600/acute-and-long-term-hemodynamic-effects-of-mitraclip-implantation-on-a-preexisting-secondary-right-heart-failure
#9
M Hünlich, E Lubos, B E Beuthner, M Puls, A Bleckmann, T Beißbarth, T Tichelbäcker, V Rudolph, S Baldus, U Schäfer, H Treede, R S Von Bardeleben, S Blankenberg, W Schillinger
Positive results of MitraClip in terms of improvement in clinical and left ventricular parameters have been described in detail. However, long-term effects on secondary pulmonary hypertension were not investigated in a larger patient cohort to date. 70 patients with severe mitral regurgitation, additional pulmonary hypertension, and right heart failure as a result of left heart disease were treated in the heart centers Hamburg and Göttingen. Immediately after successful MitraClip implantation, a reduction of the RVOT diameter from 3...
2018: BioMed Research International
https://www.readbyqxmd.com/read/29718146/echocardiographic-fluoroscopic-fusion-imaging-for-transcatheter-mitral-valve-repair-guidance
#10
Francesco F Faletra, Alberto Pozzoli, Eustachio Agricola, Andrea Guidotti, Luigi Biasco, Laura Anna Leo, Maurizio Taramasso, Elena Pasotti, Shingo Kuwata, Marco Moccetti, Felix C Tanner, Giovanni Pedrazzini, Fabian Nietlispach, Tiziano Moccetti, Michel Zuber, Francesco Maisano
The echocardiographic-fluoroscopic fusion imaging is a new imaging system which has recently become available, with the proposal to facilitate catheters and device navigation during catheter-based structural heart disease interventions. Several reports have described the early developments and the first clinical experiences, but literature focusing on the practical applications of fusion imaging technology to mitral valve transcatheter interventions, and on its potential advantages and current limitations, is still limited...
April 27, 2018: European Heart Journal Cardiovascular Imaging
https://www.readbyqxmd.com/read/29676043/mitral-valve-interventions-in-heart-failure
#11
REVIEW
Daniel Lavall, Andreas Hagendorff, Stephan H Schirmer, Michael Böhm, Michael A Borger, Ulrich Laufs
Secondary mitral regurgitation (MR) results from left ventricular dilatation and dysfunction. Quantification of secondary MR is challenging because of the underlying myocardial disease. Clinical and echocardiographic evaluation requires a multi-parametric approach. Severe secondary MR occurs in up to one-fourth of patients with heart failure with reduced ejection fraction, which is associated with a mortality rate of 40% to 50% in 3 years. Percutaneous edge-to-edge mitral valve repair (MitraClip) has emerged as an alternative to surgical valve repair to improve symptoms, functional capacity, heart failure hospitalizations, and cardiac haemodynamics...
April 19, 2018: ESC Heart Failure
https://www.readbyqxmd.com/read/29663512/specific-biomarkers-of-myocardial-inflammation-and-remodeling-processes-as-predictors-of-mortality-in-high-risk-patients-undergoing-percutaneous-mitral-valve-repair-mitraclip
#12
Oliver Dörr, Claudia Walther, Christoph Liebetrau, Till Keller, Hannes Tabert, Niklas Boeder, Matthias Bayer, Pascal Bauer, Helge Möllmann, Luise Gaede, Christian Troidl, Sandra Voss, Timm Bauer, Christian W Hamm, Holger Nef
BACKGROUND: Specific matrix metalloproteinases (MMP-2, MMP-9) and inflammatory biomarkers (hsCRP, IL-6) were found to be consistently up-regulated in severe mitral valve regurgitation (MR) and are associated with mortality in heart failure patients. The aim of the present study was to examine the prognostic value of biomarkers of cardiac inflammation and remodeling processes in predicting mortality in patients with MR undergoing percutaneous mitral valve repair (PMVR). HYPOTHESIS: We hypothesize that increased cardiac inflammation and extracellular matrix turnover is predictive for mortality in patients with severe mitral regurgitation undergoing MitraClip...
April 17, 2018: Clinical Cardiology
https://www.readbyqxmd.com/read/29656614/6-minute-walk-test-predicts-prolonged-hospitalization-in-patients-undergoing-transcatheter-mitral-valve-repair-by-mitraclip
#13
Mike Saji, Marc R Katz, Gorav Ailawadi, Timothy S Welch, Dale E Fowler, Jamie L W Kennedy, James D Bergin, Ivandito Kuntjoro, John M Dent, Michael Ragosta, D Scott Lim
BACKGROUND: The 6-minute walk test (6MWT) is a simple functional test that can predict exercise capacity and is widely employed to assess treatment outcomes. Although mortality with transcatheter mitral valve repair (TMVr) using the MitraClip (Abbott Vascular, Menlo Park, CA) is significantly less than for open mitral valve surgery in high-risk patients, identifying which patient will benefit the most from TMVr remains a concern. There are limited prognostic metrics guiding patient selection and, no studies have reported relationship between prolonged hospitalization and 6MWT...
April 15, 2018: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/29650238/incidence-timing-causes-and-predictors-of-early-and-late-re-hospitalization-in-patients-who-underwent-percutaneous-mitral-valve-repair-with-the-mitraclip-system
#14
Carmelo Grasso, Antonio Popolo Rubbio, Davide Capodanno, Sergio Buccheri, Maria Elena Di Salvo, Stefano Cannata, Salvatore Scandura, Sarah Mangiafico, Silvia Farruggio, Tatiana Salerno, Jessica De Santis, Simona Sanalitro, Anna Caggegi, Giuseppe Castania, Marco Barbanti, Piera Capranzano, Corrado Tamburino
The pattern and reasons for re-hospitalization (RH) after MitraClip implantation are not well characterized. A total of 322 consecutive MitraClip patients were included, with data stratified by RH status. Multivariate analyses were conducted to identify predictors of early (30-day) and late (30-day to 12-month) RH. Eighty-nine patients (27.6%) were readmitted to hospital during the study period and early RH occurred in 27%. The median time from MitraClip to RH was 99 days. RH was mostly related to cardiovascular causes (66...
May 15, 2018: American Journal of Cardiology
https://www.readbyqxmd.com/read/29627105/utilization-in-hospital-mortality-and-30-day-readmission-after-percutaneous-mitral-valve-repair-in-the-united-states-shortly-after-device-approval
#15
Kamil F Faridi, Jeffrey J Popma, Jordan B Strom, Changyu Shen, Eunhee Choi, Robert W Yeh
The MitraClip device for percutaneous mitral valve repair was approved by the Food and Drug Administration in the United States in October 2013. Few studies have evaluated national outcomes after this procedure in routine clinical practice. We identified adults aged ≥18 years who received percutaneous mitral valve repair from November 2013 to December 2014 in the Nationwide Readmissions Database, a publicly available administrative claims database. Procedural volumes, number of performing hospitals, individual hospital volumes, in-hospital mortality rate, and 30-day hospital readmission rate were determined...
March 1, 2018: American Journal of Cardiology
https://www.readbyqxmd.com/read/29622985/the-value-of-three-dimensional-color-doppler-trans-esophageal-echocardiography-in-predicting-the-number-of-mitraclip-devices-needed-during-the-procedure
#16
Hani M Mahmoud, Ali M Al-Ameen, Mohamed H Hassan, Tarek Badr, Hesham Nieem, Ahmed A Shaheen, Abdullah E Ghabashi
Purpose: During MitraClip procedure, one or more clips might be needed to effectively reduce the mitral regurgitation (MR). Three-dimensional vena-contracta (3D-VC) assessed by color Doppler three-dimensional trans-esophageal echocardiography (3D-TEE) was proven to be well correlated with MR severity. However, its role in predicting the number of MitraClip devices needed during the procedure was not fully determined. Aim of this study is to assess the predictive value of 3D-VC area & length in determining the number of clips needed during the procedure...
December 2017: The Egyptian heart journal: (EHJ): official bulletin of the Egyptian Society of Cardiology
https://www.readbyqxmd.com/read/29594183/patient-specific-cardiac-phantom-for-clinical-training-and-preprocedure-surgical-planning
#17
Justin Laing, John Moore, Reid Vassallo, Daniel Bainbridge, Maria Drangova, Terry Peters
Minimally invasive mitral valve repair procedures including MitraClip® are becoming increasingly common. For cases of complex or diseased anatomy, clinicians may benefit from using a patient-specific cardiac phantom for training, surgical planning, and the validation of devices or techniques. An imaging compatible cardiac phantom was developed to simulate a MitraClip® procedure. The phantom contained a patient-specific cardiac model manufactured using tissue mimicking materials. To evaluate accuracy, the patient-specific model was imaged using computed tomography (CT), segmented, and the resulting point cloud dataset was compared using absolute distance to the original patient data...
April 2018: Journal of Medical Imaging
https://www.readbyqxmd.com/read/29575435/implication-of-pulmonary-hypertension-in-patients-undergoing-mitraclip-therapy-results-from-the-german-transcatheter-mitral-valve-interventions-trami-registry
#18
Eike Tigges, Stefan Blankenberg, R Stephan von Bardeleben, Christine Zürn, Raffi Bekeredjian, Taoufik Ouarrak, Horst Sievert, Georg Nickenig, Peter Boekstegers, Jochen Senges, Wolfgang Schillinger, Edith Lubos
AIMS: We sought to evaluate the impact of pulmonary hypertension on outcomes following MitraClip therapy. METHODS AND RESULTS: The 643 patients in the TRAnscatheter Mitral valve Interventions (TRAMI) registry were divided into three groups according to echocardiographically graded systolic pulmonary artery pressure (sPAP) (Group 1: patients with sPAP of ≤36 mmHg; Group 2: patients with sPAP of 37-50 mmHg; Group 3: patients with sPAP of >50 mmHg) and followed for 1 year...
March 2018: European Journal of Heart Failure
https://www.readbyqxmd.com/read/29546746/transcatheter-therapies-for-tricuspid-regurgitation-coaptation-augmentation-devices
#19
Edwin C Ho, Neil P Fam
Advancements in transcatheter technology has increased the number of therapeutic options for patients with tricuspid regurgitation. One category of repair devices attempts to augment leaflet coaptation by either leaflet plication or by functioning as a space occupying device. These include the MitraClip (Abbott, Santa Clara, CA, USA), PASCAL (Edwards Lifesciences, Irvine, CA, USA) and FORMA (Edwards Lifesciences, Irvine, CA, USA) devices. All three have been successfully implanted with promising short term echocardiographic and clinical outcomes...
March 15, 2018: Minerva Cardioangiologica
https://www.readbyqxmd.com/read/29545259/distinct-hemodynamic-changes-after-interventional-mitral-valve-edge-to-edge-repair-in-different-phenotypes-of-heart-failure-an-integrated-hemodynamic-analysis
#20
Benedikt Schrage, Daniel Kalbacher, Michael Schwarzl, Nicole Rübsamen, Christoph Waldeyer, Peter Moritz Becher, Eike Tigges, Daniel Burkhoff, Stefan Blankenberg, Edith Lubos, Ulrich Schäfer, Dirk Westermann
BACKGROUND: Percutaneous mitral valve edge-to-edge repair (pMVR) with a MitraClip is beneficial for the clinical symptoms of patients irrespective of the ejection fraction (EF). Nevertheless, the consequences on hemodynamics are poorly understood. Therefore, we used data from noninvasive pressure-volume loops to investigate the left ventricular (LV) remodeling of patients after pMVR dependent on their baseline EF. METHODS AND RESULTS: In 130 patients with successful pMVR, the end-diastolic pressure-volume relationship (EDPVR) and end-systolic pressure-volume relationship were estimated noninvasively from echocardiographic data...
March 15, 2018: Journal of the American Heart Association
keyword
keyword
7760
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"